Prediction: $1,000 Invested in Viking Therapeutics Today Will Be Worth This Much in 5 Years

Viking Therapeutics is advancing its weight-loss drug candidates, particularly SC VK2735, through Phase 3 trials with promising clinical results. Under a bullish scenario with $1 billion in 2031 revenue, a $1,000 investment could grow to approximately $1,875 by 2031 (13.4% annualized returns). However, significant risks exist including potential Phase 3 trial failures, increased competition, market growth uncertainties, and potential dilutive financing needs.